GL1X · GenesisL1 explorer

MolNFT v1 · #183019 · protein

Glutathione-S-transferase glig mutant N27A

7NCE · Glutathione S-transferase glig: “Glutathione-S-transferase glig mutant N27A”. X-ray diffraction, 16 pockets (best druggability 0.79). MolNFT v1 #183019 on GenesisL1: 3D structure, binding sites and pockets in GL1X.

PDB
7NCE
Type
protein
Length
1,430 residues
Chains
6
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Glutathione S-transferase glig
UniProt
B0Y813
Pockets
16 · best druggability 0.79

Structure

x-ray diffraction · 4 distinct chains · 50% helix, 9% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
A, B, DGlutathione S-transferase gligprotein23850% helix, 9% strandB0Y813
CGlutathione S-transferase gligprotein24050% helix, 9% strandB0Y813
EGlutathione S-transferase gligprotein23951% helix, 9% strandB0Y813
FGlutathione S-transferase gligprotein23751% helix, 9% strandB0Y813

Ligands and binding sites

  • EDO · 1,2-ethanediol · additive · 4 copies · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

16 pockets found on a 1 Å grid, 10 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
19200.790.8184empty
211130.780.7971empty
310560.770.7979empty
44860.750.8346EDO
54640.710.8140empty

Interfaces

5 interfaces between chains.

  • E–F · 2256 Ų buried · 43 hydrogen bonds · protein-protein
  • C–D · 2248 Ų buried · 37 hydrogen bonds · protein-protein
  • A–B · 2218 Ų buried · 45 hydrogen bonds · protein-protein
  • A–C · 548 Ų buried · 8 hydrogen bonds · protein-protein
  • D–E · 507 Ų buried · 4 hydrogen bonds · protein-protein

Compared structures

  • 7NCE · Glutathione-S-transferase GliG mutant N27A · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.